Clinical Trial Update: Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation [Phase 4]

View source ↗

Summary

Phase 4 trial update on converting from mycophenolic acid (MPA) to everolimus (Zortress) for GI toxicity after kidney transplantation; study terminated with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Disorder Functional
• Kidney Transplant Rejection

Drugs mentioned

• Mycophenolic acid (mycophenolic acid)
• Zortress (everolimus)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Kidney Transplant Rejection, Gastrointestinal Disorder, Functional | Phase 4 | Status: TERMINATED | Results posted: 2020-08-10